Open an account

Eupraxia Pharmaceuticals

EPRX · TORONTO

$6.87−$0.72 (−9.49%)TodayMarket closed ·
Prev close $7.59

About EPRX

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia and currently employs 49 full-time employees. The company went IPO on 2021-03-09. The firm is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The firm also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.

Employees
49
Headquarters
Victoria, British Columbia
Listed
Mar 9, 2021
Sector
Health Care
Industry
Biotechnology
Website
eupraxiapharma.com

EPRX key statistics

Market cap
701.91M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.02M
Volume
348.80K
Open price
$7.51
High today
$7.61
Low today
$6.70
52 Week high
$9.32
52 Week low
$5.25

Eupraxia Pharmaceuticals (EPRX) at a glance

Eupraxia Pharmaceuticals (EPRX) last traded at $6.87, with a market cap of 701.91M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.70 and $7.61. The current price is 2.5% above the day's low and 9.7% below its high.

Volume so far is 348.80K shares, below the average of 1.02M shares a day.

Over the past year Eupraxia Pharmaceuticals has ranged from $5.25 to $9.32, and now sits 40% of the way up that range.

The average analyst price target is $12.25, 78.3% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $12.25
Low
$10.12
Now
$6.87
High
$15.87

EPRX news

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

  • Press releaseGlobe Newswire

    Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.